Fujifilm: Latest $1.6bn spend to help quadruple CDMO’s mammalian capacity
Another $1bn+ investment boost, this time at sites in Denmark and Texas, will push Fujifilm Diosynth Biotechnologies into the top tier of CDMOs based on cell culture capacity. The $1.6 billion will be used to expand cell culture manufacturing capabilities at contract development and manufacturing ...
Charles River opens a plasmid DNA plant in the UK, Batavia Biosciences is building a commercial vaccine facility in the Netherlands, and OrganaBi ...- Astellas will codevelop immunostimulatory antibody-drug conjugates (iADCs) for three biological targets through a partnership with Sutro Biopharm ...
- The investment will expand drug substance production capabilities at facilities in Blanchardstown and Athlone run by AstraZeneca subsidiary Alexi ...
- Cell and gene therapy developers need staff with skills according to McKinsey & Company, which says making such therapies is laborious, compl ...
Recent Tweets
-
RT @Dan5tanton: Two co-founders of Taiwanese firm JHL Biotech were sentenced last month for plotting to steal trade secrets from Ge… https://t.co/0iclK4yS7h
3 months ago
-
RT @frankvinluan: Shutdown comes 8 months after FDA sent a warning letter about a #microbiome metabolic therapy the #biotech was test… https://t.co/FgtTS54Yj0
3 months ago
-
RT @Dan5tanton: A win for CDMO Catalent as it further strengthens its global network, but potentially a loss to the UK taxpayer, wh… https://t.co/Ex9CNdbcf0
3 months ago
-
RT @Dan5tanton: The US Department of Health and Human Services #HHS has terminated a long-term #CDMO partnership with Emergent BioS… https://t.co/bAbKWb3uqQ
8 months ago
